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Abstract Introduction Earlier diagnosis and better treat-
ment have increased the survival rates of cancer patients.
This warrants research on return to work of cancer survi-
vors. What is the return to work rate following early-stage
breast cancer? What is the effect of the type of treatment
and cancer-related symptoms on return to work? Methods
Our occupational health department registers sickness
absence of about 50,000 employees. In the period 2001–
2005 we counted 154 cases of newly diagnosed breast
cancer of which 72 were eligible for analysis. In these
women, return to work was followed for 24 months after
diagnosis and linked to the type of treatment and cancer-
related symptoms. Results The mean duration of absence
with early-stage breast cancer was 11.4 ± 5.5 months;
35% of patients were absent longer than one year and 4
patients did not return to work within two years after
diagnosis. The duration of absence depended on the type of
treatment and was significantly longer in patients who
underwent chemotherapy (hazard rate [HR] = 0.31; 95%
confidence interval [CI] = 0.12–0.81) or multimodal
treatment (HR = 0.24; 95% CI = 0.10–0.54). Women
started working about 4 months after the end of therapy
irrespective of the type of treatment. At that moment,
reaching above shoulder level was impaired in 11 patients
(15%) which significantly delayed partial return to work
(HR = 0.48; 95% CI = 0.23–0.98) but not full return to
work (HR = 0.63; 95% CI = 0.31–1.26). Fatigue was
reported by 9 patients (13%) and neither postponed partial
return to work nor full return to work. Conclusions The
time taken to return to work after early-stage breast cancer
was principally determined by the type of treatment.
Keywords Breast cancer  Absence duration 
Treatment  Cancer-related symptoms  Return to work
Introduction
Breast cancer is the most prevalent type of cancer in the
Netherlands constituting about 33% of all newly diagnosed
cancer cases in women. In 2003 the incidence was 123.5
per 100,000 women. Breast cancer is commonly treated by
various combinations of (breast conserving or radical)
surgery, radiation therapy, chemotherapy, and hormone
therapy. The selection of treatment depends on the age and
menopausal status of the patient, as well as the stage of the
disease, histologic and nuclear grade of the primary tumor,
estrogen-receptor (ER) and progesterone-receptor (PR)
status, measures of proliferative capacity, and HER2/neu
gene amplification. Most women are diagnosed when they
are still of working age and have an early-stage disease that
has good prognosis given the improvement in breast cancer
treatment.
The increased survival rates warrant attention for return
to work of breast patients [1–3]. Return to work can be
regarded as social recovery and adds to the survivors’
quality of life [4, 5]. Disease-related, person-related, and
work-related factors influence return to work after cancer.
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Cancer type and treatment determine the likelihood of
returning to work [6, 7]. Personal sociodemographic
characteristics, such as age, gender, education, income, and
marital status, were not found to be associated with return
to work of cancer survivors [8]. A changed attitude of
patients towards work reflecting reduced importance and a
decrease in work aspirations, was negatively associated
with return to work after cancer [9]. One fifth of cancer
patients who returned to work reported deterioration in
their job satisfaction and career prospects [10]. Manual
work and work demanding physical efforts were also
negatively associated with return to work of cancer survi-
vors [8]. In contrast, social support and a supportive work
environment facilitated return to work [8–11]. Discretion
over work hours and amount of work were also positively
associated with return to work of cancer survivors [12].
Cancer-related symptoms perceived by patients might
affect work resumption. The most common breast cancer-
related symptoms are therapy side effects, arm symptoms,
fatigue, breast symptoms, and sleep disturbance [13].
Shoulder function impairment is a common complication
after axillary lymph node dissection [14]. Lymphedema is
an infrequent but potentially severe long-term complication
of axillary lymph node dissection [15]. Fatigue is one of
the best known cancer-related symptoms, debilitating daily
activities for a long time following diagnosis [16]. Fatigue
has been reported to have the greatest impact on the quality
of life of cancer survivors [17, 18]. Spelten et al. reported
that fatigue at 6 months predicted longer sick-leave in a
sample of 235 patients suffering different types of cancer
[19]. The present study investigated whether treatment and
cancer-related symptoms interfered with return to work
after early-stage (i.e., stage 0 through II) breast cancer.
Two research questions will be addressed:
(i) What is the return to work rate following early-stage
breast cancer?
(ii) What is the effect of the type of treatment and cancer-
related symptoms on return to work?
Method
Our occupational health department registers sickness
absence data and diagnostic codes of on average 50,000
employees working in four north-eastern provinces
(Groningen, Friesland, Drenthe, and Overijssel) of the
Netherlands. In the period January 2001 through December
2005, our registration system counted 154 cases of newly
diagnosed breast cancer. Forty-one of these patients were
excluded because their medical data were not available
anymore, as their employer ended the association with our
occupational health service. The inclusion criteria for the
remaining 113 patients were:
• Age 18 to 65 years
• Employed
• Newly diagnosed breast cancer
• Early stage (stage 0, I or II) breast cancer
• No pre-existent chronic disease
Investigation of the medical files showed that 23 patients
had more advanced disease (stage III or IV) and 7 patients
suffered from recurrent tumours. Of the remaining 83
patients with early-stage breast cancer, 11 were excluded
because they had a pre-existent chronic disease which
might influence return to work. From the medical files of
the remaining 72 patients, we retrieved the type and dura-
tion of treatment. All patients underwent surgery.
According to the post-operative treatment, four groups were
distinguished: no adjuvant therapy (n = 11); locoregional
radiotherapy (n = 18); systemic chemotherapy (n = 9);
and multimodal treatment (n = 32) including chemother-
apy and radiotherapy. In 2 patients the type of post-
operative treatment was not documented in the medical file.
From the medical files, we also retrieved cancer-related
arm symptoms (shoulder function impairment and lymph-
edema) recognized by the occupational physician, and
fatigue mentioned by the patients at the start of return to
work. Some, but not all occupational physicians measured
the range of motion of the shoulder to quantify function
impairment. None of the occupational physicians used
instruments to quantify lymphedema or fatigue. Therefore,
we assessed cancer-related symptoms dichotomously as
being present (i.e., documented in the medical file) or
absent (i.e., not documented in the medical file).
The period between the first day of sick-leave and both
partial return to work (defined as working part of the
contracted hours per week) and full return to work (defined
as working the normal contracted hours per week) was
calculated in months. Although measurement in months is
quite imprecise, it facilitates the comparison of our results
with those of other studies on return to work after cancer.
Cox regression analysis was used to predict the duration
until (partial) return to work from a model including age
(entered as numerical data), type of treatment (entered as
categorical data relative to the group without adjuvant
treatment), and cancer-related symptoms (entered as cate-
gorical data relative to the group without cancer-related
symptoms). Cox regression analysis produces hazard ratios
(HR) representing the effect of the prognostic variable on the
hazard or risk of an event. A HR \1 expresses a prolonged
duration until (partial) return to work, and a HR [1 a shorter
duration. The Wald-statistic is a measure for the relative
influence of the prognostic factor on (partial) return to work.
Ethical approval was sought from the Medical Ethics
Committee of the University Medical Center Groningen,
who advised that ethical approval was not required.
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Results
The data of 72 patients with early-stage breast cancer were
eligible for analysis. They were older than the excluded
patients and had less contracted hours/week, but were
employed for a longer period of time (Table 1). The mar-
ital status did not differ between included patients and
excluded patients. Among the excluded patients were more
employees who worked as cleaners; this can be explained
by the fact that a cleaning company ended the association
with our occupational health service in 2003. The excluded
patients were also longer absent (20.3 ± 5.6 months) than
those who were included (11.4 ± 5.5 months).
Of the included patients, 25 (35%) were absent longer
than 1 year and 4 (6%) did not return to work within
2 years after diagnosis. All included patients underwent
surgery in the first month of sick-leave; axillary lymph
node dissection was performed in 41 patients (57%). The
period of time between surgery and return to work in
patients without adjuvant treatment was not shorter than
the period of time between the end of adjuvant therapy and
return to work, as is shown in Table 2.
Of the patients who did not receive adjuvant therapy 9%
was absent longer than one year and everybody returned to
work within two years after diagnosis. Eighteen patients
underwent locoregional radiotherapy and 3 of them were
absent longer than one year. Nine patients underwent sys-
temic chemotherapy; 2 of them were absent longer than
one year and 1 patient did not return to work within two
years after diagnosis. Most patients (n = 32) received
multimodal treatment; 18 of them were absent longer than
one year and 3 patients did not return to work within two
years after diagnosis.
Cancer-related symptoms were documented by the
occupational physician at the moment of return to work.
Reaching above shoulder level was impaired in 11 patients.
They started working about 2 months later than patients
without impairments (Table 2), although full return to
work was not delayed relative to patients without impair-
ments as is shown in Table 3.
Lymphedema was observed in 1 patient and therefore
this cancer-related symptom was not included in the mul-
tivariate regression analysis. Fatigue was reported by 9
patients but did not postpone return to work (Table 3).
Table 3 shows that the age of women was not related to
return to work. The high Wald-statistic showed the type of
treatment to be an important determinant of return to work.
Both chemotherapy and multimodal treatment delayed
return to work significantly relative to patients who did not
receive adjuvant treatment. However, multimodal treat-
ment postponed return to work more than systemic
chemotherapy did. Cancer-related symptoms had little
effect on return to work as is reflected in the low Wald-
statistics. Impaired shoulder function significantly delayed
partial return to work but not full return to work.
Discussion
The mean duration of sickness absence with early stage
breast cancer was 11.4 ± 5.5 months. About 35% of
patients was absent longer than one year and 6% of patients
Table 1 Patient characteristics
Characteristics of 154 patients
with newly diagnosed breast-
cancer between January 2001
and December 2005 in a
population of about 50,000
employees. Results are
presented either as number (N)
with row percentages (row%) or
as mean ± standard deviation
Included Excluded Total
N (row%) 72 (47%) 82 (53%) 154
Age at diagnosis (years) 49.2 ± 7.0 41.9 ± 10.0 46.2 ± 9.1
Marital status (number and row%)
Single 17 (50%) 17 (50%) 34
Married 41 (43%) 55 (57%) 96
Divorced 14 (58%) 10 (42%) 24
Contracted hours per week (hours) 25.4 ± 13.5 31.0 ± 10.9 27.6 ± 12.8
Duration of employment (years) 14.3 ± 11.2 9.2 ± 8.4 12.2 ± 10.4
Occupation (number and row%)
Health care 24 (44%) 30 (56%) 54
Postal services 13 (59%) 9 (41%) 22
Front-office services 9 (47%) 10 (53%) 19
Cleaning 3 (20%) 12 (80%) 15
Administrative 5 (42%) 7 (58%) 12
Shop assistants 6 (60%) 4 (40%) 10
Other 6 (55%) 5 (45%) 11
Missing 6 (55%) 5 (45%) 11
Duration of absence (months) 11.4 ± 5.5 20.3 ± 5.6 16.8 ± 5.5
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did not return to work within two years after diagnosis.
Without adjuvant treatment, women returned to work after
7.2 ± 5.2 months. This is nearly two months later than the
average 5.4 months reported by Drolet et al. [20, 21].
Patients who received adjuvant treatment were absent from
work 7 to 11 months, whereas the contracted hours were
reached 9 to 13 months after taking sick-leave.
The majority of women diagnosed with breast cancer
undergo intensive treatment, often involving multiple
modalities. The results of this study indicated that return to
work was particularly delayed by the type of treatment.
The strong relation between treatment modalities and the
length of sick-leave was reported before [6, 7]. We found
that work resumption was most postponed by multimodal
therapy, including radiotherapy and chemotherapy.
Radiotherapy was performed every week day continuing
for a period of five weeks. The daily treatment interfered
with work in all cases. Patient-related factors obstructing
work during chemotherapy were the side effects, the
emotional burden of treatment, and the changed attitude
towards work as patients were preoccupied with their dis-
ease at that moment. Besides, we hypothesize that
occupational physicians as well as employers and co-
workers do not think it proper for cancer patients to work
during therapy. In our study population, only two patients
worked between rounds of chemotherapy. Future research
Table 2 Univariate analysis of return to work following early-stage breast cancer











No adjuvant treatment 11 51.1 ± 7.8 1.4 ± 1.1 4.7 ± 5.4 5.9 ± 5.1 7.2 ± 5.2
Locoregional radiotherapy 18 51.1 ± 5.8 4.4 ± 4.1 3.0 ± 3.0 7.3 ± 3.4 9.0 ± 3.7
Systemic chemotherapy 9 48.9 ± 7.4 5.3 ± 1.1 5.5 ± 3.2 10.6 ± 3.2 12.3 ± 4.7
Multimodal treatment 32 47.5 ± 6.5 6.9 ± 1.3 3.8 ± 4.0 11.1 ± 4.9 13.6 ± 5.3
Total 70 49.2 ± 6.7 5.1 ± 2.3 3.9 ± 3.9 9.2 ± 4.8 11.2 ± 5.4
Cancer-related symptoms
None 51 48.0 ± 7.4 4.9 ± 2.4 3.6 ± 3.2 9.2 ± 5.2 10.8 ± 5.6
Shoulder function impairment 11 51.8 ± 7.4 5.3 ± 2.0 6.4 ± 6.2 11.7 ± 5.3 12.9 ± 5.0
Lymphedema 1 46.4 7.0 4.6 11.6 22.8
Fatigue 9 49.1 ± 7.1 5.9 ± 2.0 2.2 ± 2.1 7.8 ± 2.4 12.1 ± 5.5
Total 72 48.7 ± 7.3 5.1 ± 2.3 3.9 ± 3.9 9.5 ± 5.0 11.4 ± 5.5
a After diagnosis
Univariate analysis of return to work (RtW) with regard to the type of treatment and cancer-related symptoms identified at the start of return to
work. The table shows mean ± standard deviation of age (in years at the time of diagnosis) and the end of treatment, partial RtW and full RtW in
months after the first day of sick-leave following early-stage (0 through II) breast cancer. The latent time is the period of time that passed
between the end of treatment and partial RtW
Table 3 Multivariate analysis of return to work following early-stage breast cancer
Partial RtW Full RtW
HR (95% CI) Wald HR (95% CI) Wald
Age 0.97 (0.93–1.02) 1.38 0.98 (0.94–1.03) 0.68
Type of treatment 16.45 15.43
Locoregional radiotherapy 0.51 (0.22–1.16) 2.58 0.63 (0.28–1.41) 1.23
Systemic chemotherapy 0.27 (0.10–0.72)** 6.86 0.31 (0.12–0.81)* 5.73
Multimodal therapy 0.19 (0.08–0.45)** 13.84 0.24 (0.10–0.54)** 11.86
Cancer-related symptoms 6.42 2.38
Shoulder function impairment 0.48 (0.23–0.98)* 4.04 0.63 (0.31–1.26) 1.74
Fatigue 1.67 (0.76–3.64) 1.65 0.79 (0.37–1.70) 0.37
The results of Cox regression analysis including all prognostic factors of return to work (RtW) after early-stage (0 through II) breast cancer. Age
was entered as numerical data and both the type of treatment and cancer-related symptoms were entered as categorical data. The table shows
hazard ratios (HR) and their 95% confidence intervals (95% CI), with HR \1 expressing prolonged duration until (partial) work resumption and
HR [1 a shorter duration relative to the group without adjuvant treatment (type of treatment) or relative to the group without symptoms (cancer-
related symptoms); * P \ 0.05 and ** P \ 0.01
270 J Occup Rehabil (2008) 18:267–272
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should investigate these contexts opposing work resump-
tion. It would also be interesting to study the effects of
different types of chemotherapy on return to work.
Fatigue is one of the most distressing and debilitating
symptoms reported by cancer survivors. De Jong et al.
evaluated the prevalence and course of fatigue in patients
with breast cancer [22]. Women who underwent radical
mastectomy were more fatigued than those who underwent
lumpectomy. Radiotherapy and chemotherapy were also
associated with fatigue. The prevalence of fatigue
increased significantly after the start of chemotherapy with
a different impact of the type of chemotherapy [23]. In the
doxorubicin group a direct increase in fatigue was found,
whereas in the group treated with cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) a moderate direct
increase occurred, followed by a delayed strong increase.
High rates of fatigue were not only reported during treat-
ment but also afterwards. Pain, impaired quality of sleep,
and depression were highly consistent with fatigue,
although it is not clear whether it is these symptoms that
cause fatigue or vice versa. Fatigue scores were associated
with a decrease in daily functioning and were found to be
strongly related to the time taken to resume work [17]. In
our study, fatigue was mentioned by 9 patients (13%),
particularly those who received multimodal treatment. It
has been reported that fatigue is a persistent problem for
25% of disease-free breast cancer patients during a 2-year
period [24]. The lower prevalence of fatigue in our study
means that either patients did not mention fatigue or the
occupational physician did not inquire about it. The time
taken to return to work was not longer in patients reporting
fatigue than in those without complaints.
Hayes et al. [25] studied upper body functioning in a
population-based sample of 214 women. They found evi-
dence for impaired upper body flexibility following
radiation treatment. Further analysis identified five distinct
task groups to be most burdensome, specifically whole body
function, flexibility, carrying/upper-body strength, hand and
weighted flexion tasks [26]. Rietman et al. reported that
axillary radiation predicted an additional decrease in the
range of motion of the shoulder [27]. They found an impaired
range of motion in 9–16% of 55 patients who underwent a
modified radical mastectomy or a segmental mastectomy
with axillary lymph node dissection [28]. In our study,
shoulder function impairment was found in 11 patients
(15%), particularly in those who received radiotherapy or
multimodal treatment. Their partial return to work was sig-
nificantly delayed relative to patients without complaints.
Patients with shoulder function impairment resumed their
work about two months later than those without complaints.
The results of this study could have been biased by the
selection of 72 out of 154 patients and by their allocation to
rather small therapy groups which was not random but
according to Dutch treatment guidelines [29]. The patients
who were included in analysis were older than those who
were excluded, but our results showed that age was not a
significant determinant of return to work following early-
stage breast cancer. The included patients worked less
hours per week and were employed for a longer time than
those excluded. Both factors might facilitate return to work
and herewith underestimate the duration of sickness
absence due to early-stage breast cancer. The excluded
patients were longer absent indeed, but this might also be
the result of more advanced breast cancer or the presence
of another disease (co-morbidity).
A major limitation of the study is the validity of the
cancer-related symptoms. For this study we retrospec-
tively reviewed the medical files of patients. Arm
symptoms and fatigue were dichotomized as being docu-
mented in the medical file or not. When prominent, the
symptoms will have been mentioned by the patient and
documented in her medical file. Self-reported ‘‘heaviness
in the arm in the past year’’ and ‘‘swelling now’’ was
found to be predictive of lymphedema [30]. But it is not
known whether occupational physicians specifically asked
for cancer-related symptoms, or which symptoms the
patients were inquired about. Verbeek et al. interviewed
one hundred occupational physicians of a cohort of cancer
survivors about return to work management [31]. For
knowledge of cancer and treatment, only 3% of them had
optimal performance. They concluded that the quality of
occupational rehabilitation of cancer survivors can be
improved, especially with regard to communication with
treating physicians.
Although exploratory, this study showed that treatment
and to a lesser extent arm symptoms interfered with work
resumption after early-stage breast cancer. For practice,
this means that occupational physicians should be better
educated about topical cancer treatments, the side-effects,
and cancer-related symptoms. Moreover, the use of vali-
dated measures to quantify arm symptoms in breast cancer
survivors should be encouraged, as well as examination of
other cancer-related symptoms such as sleeping problems,
distress, and depressed mood. Although severely affecting
the quality of life of patients, these symptoms are often
neglected by treating physicians. The occupational physi-
cian could advise patients on coping with these symptoms
or refer them to specific interventions. Gradual occupa-
tional rehabilitation in suitable work could help cancer
survivors to regain self-confidence in their capacities and
improve quality of life.
This study investigated cancer-related factors, but more
research is also needed on work-related factors affecting
return to work after cancer. Providing patients with an
educational leaflet on work resumption had no effect on
return to work [32]. The occupational physician could play
J Occup Rehabil (2008) 18:267–272 271
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a key role in workplace education about cancer, in order to
create a supportive work environment preventing co-
worker and supervisor ignorance from making the patient’s
work resumption more stressful.
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